A Vancouver biotechnology company will now be offering its high-grade laboratory-synthesized psychedelic compound to a Toronto-based contract research organization (CRO) for its investigational studies.
On Friday, PharmAla Biotech Holdings Inc. (CSE: MDMA) announced that it had signed an agreement to become an exclusive MDMA supplier for InterVivo Solutions and its client companies.
Through the new agreement, PharmAla will supply InterVivo and its clients with good manufacturing practice (GMP) clinical-grade LaNeo MDMA and so-called Engineering MDMA intended for research on animals. The arrangement will grant InterVivo’s clients’ priority access to PharmAla’s products at reduced prices for research purposes.
Read more: WITHIN ‘Ceremonial Psychedelic Treatment Center’ opens in Texas
Read more: TheraPsil launches Project Solace, Filament Health offers support
LaNeo MDMA is a trademark registered clinical-grade product developed by PharmAla that the company claims is the only variation of the chemical appropriate for scientific research.
PharmAla has constructed a cGMP MDMA value chain business model that it claims is the first of its kind in North America. The company says that value chain encompasses GMP manufacturing of active pharmaceutical ingredients (APIs) and drug product formulation. The organization is also engaged in pre-clinical and proof-of-concept research for other psychedelic compounds.
“As a current client of InterVivo, we have seen the excellence of their work first-hand. We’ve been impressed with both their scientific rigour, and the speed with which they have developed data sets to support our novel IP. I’m thrilled that we have been named the exclusive supplier of MDMA for both InterVivo and their research clients – and I’m sure that those clients will appreciate having a stable source of drug to support their efforts,” said Nick Kadysh, CEO at PharmAla.
InterVivo is a CRO with expertise in neuropsychiatric and neurological diseases that offers research services utilizing translational animal models to assess the pharmacokinetics, safety, efficacy and toxicology of new drugs. The company has scientific operations that span across Canada, Poland, Ireland and the UK.
“We’re pleased to be able to offer our global client base a reliable and high-quality supply of reference MDMA through this exclusive supply agreement with PharmAla. Our hope is this will streamline and further propel our client’s research efforts to uncover and optimize the key properties of psychedelics and entactogenic medicines,” said Sal Lemus, Director of Sales and Marketing at InterVivo.
